Dexamethasone compared to prednisolone for adults with acute

  • Slides: 7
Download presentation
Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final

Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group by Boris Labar, Stefan Suciu, Roel Willemze, Petra Muus, Jean-Pierre Marie, Georges Fillet, Zwi Berneman, Branimir Jaksic, Walter Feremans, Dominique Bron, Harm Sinnige, Martin Mistrik, Gerard Vreugdenhil, Robrecht De Bock, Damir Nemet, Caroline Gilotay, Sergio Amadori, and Theo de Witte haematol Volume 95(9): 1489 -1495 August 31, 2010 © 2010 by Ferrata Storti Foundation

EORTC ALL-4 protocol: study design. Boris Labar et al. Haematologica 2010; 95: 1489 -1495

EORTC ALL-4 protocol: study design. Boris Labar et al. Haematologica 2010; 95: 1489 -1495 © 2010 by Ferrata Storti Foundation

Scheme of the ALL-4 protocol. Boris Labar et al. Haematologica 2010; 95: 1489 -1495

Scheme of the ALL-4 protocol. Boris Labar et al. Haematologica 2010; 95: 1489 -1495 © 2010 by Ferrata Storti Foundation

Patients’ characteristics according to the first randomization. Boris Labar et al. Haematologica 2010; 95:

Patients’ characteristics according to the first randomization. Boris Labar et al. Haematologica 2010; 95: 1489 -1495 © 2010 by Ferrata Storti Foundation

Treatment outcome for all patients and for patients randomized to receive dexamethasone or prednisolone.

Treatment outcome for all patients and for patients randomized to receive dexamethasone or prednisolone. Boris Labar et al. Haematologica 2010; 95: 1489 -1495 © 2010 by Ferrata Storti Foundation

The 6 -year event-free survival (A) and overall survival (B), disease-free survival from complete

The 6 -year event-free survival (A) and overall survival (B), disease-free survival from complete remission (C) and survival from complete remission (D) according to randomization to dexamethasone or prednisolone. Boris Labar et al. Haematologica 2010; 95: 1489 -1495 © 2010 by Ferrata Storti Foundation

Grade III–IV toxicity according to first randomization (dexamethasone versus prednisolone) and treatment phase. Boris

Grade III–IV toxicity according to first randomization (dexamethasone versus prednisolone) and treatment phase. Boris Labar et al. Haematologica 2010; 95: 1489 -1495 © 2010 by Ferrata Storti Foundation